Wild Type BRCA1 but not the disease associated mutants have been shown to bind in vitro to SUMO E2 conjugating enzyme Ubc9 and this is responsible for both ER-alpha activation and tumor suppression of breast and ovarian cancer cells [31, 34]. The gene discussed is BRCA1; the disease is neoplasm.